Skip to content

Paul Greengard

Rockefeller University

2 papers in the library · 407 citations · publishing 1974-2003

Papers

Diverse Psychotomimetics Act Through a Common Signaling Pathway

Science November 21, 2003 Per Svenningsson, Eleni T. Tzavara, Robert Carruthers et al. 312 citations

Three drug classes—dopaminergic agonists (e.g., D-amphetamine), serotonergic agonists (e.g., LSD), and glutamatergic antagonists (e.g., PCP)—produce schizophrenia-like effects in animals. A common signaling pathway involving the protein DARPP-32 mediates these effects. DARPP-32 is phosphorylated or dephosphorylated at three sites, leading to synergistic inhibition of protein phosphatase-1 and regulation of downstream effectors GSK-3, CREB, and c-Fos. In mice lacking DARPP-32 or with point mutations at its phosphorylation sites, the drugs' effects on sensorimotor gating and repetitive movements were strongly reduced, indicating DARPP-32's essential role in these psychotomimetic actions.

Serotonin-Sensitive Adenylate Cyclase in Neural Tissue and Its Similarity to the Serotonin Receptor: A Possible Site of Action of Lysergic Acid Diethylamide

Proceedings of the National Academy of Sciences March 1, 1974 James A. Nathanson, Paul Greengard 95 citations

An enzyme called adenylate cyclase, found in the thoracic ganglia of an insect nervous system, is specifically activated by low concentrations of serotonin. This activation is selectively blocked by very low concentrations of D-lysergic acid diethylamide (LSD), 2-bromo-LSD, and cyproheptadine, substances known to block certain serotonin receptors in living organisms. The inhibition is competitive with respect to serotonin, and the inhibitory constant of LSD for this serotonin-sensitive adenylate cyclase is 5 nM. These findings suggest that the serotonin receptor in neural tissue is closely linked to this enzyme, which may mediate serotonergic neurotransmission, and that some physiological effects of LSD might occur through interaction with this enzyme.